BeOne Medicines Ltd. (ONC)

Market Cap	35.48B
Revenue (ttm)	4.18B
Net Income (ttm)	-392.37M
Shares Out	118.65M
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	154.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	543,060
Open	288.61
Previous Close	301.13
Day's Range	288.07 - 299.29
52-Week Range	155.75 - 308.87
Beta	0.28
Analysts	Strong Buy
Price Target	332.44 (+11.18%)
Earnings Date	Aug 6, 2025

About EXAI

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Financial Performance

In 2024, BeOne Medicines's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in EUR

Analyst Summary

According to 9 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $332.44, which is an increase of 11.18% from the latest price.

Price Target

$332.44

(11.18% upside)

Analyst Consensus: Strong Buy